Glycosylation of glycolipids in cancer: Basis for development of novel therapeutic approaches

Jose L. Daniotti, Aldo Alejandro Vilcaes, Vanina Torres Demichelis, Fernando M. Ruggiero, Macarena Rodriguez-Walker

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Altered networks of gene regulation underlie many pathologies, including cancer. There are several proteins in cancer cells that are turned either on or off, which dramatically alters the metabolism and the overall activity of the cell, with the complex machinery of enzymes involved in the metabolism of glycolipids not being an exception. The aberrant glycosylation of glycolipids on the surface of the majority of cancer cells, associated with increasing evidence about the functional role of these molecules in a number of cellular physiological pathways, has received considerable attention as a convenient immunotherapeutic target for cancer treatment. This has resulted in the development of a substantial number of passive and active immunotherapies, which have shown promising results in clinical trials. More recently, antibodies to glycolipids have also emerged as an attractive tool for the targeted delivery of cytotoxic agents, thereby providing a rationale for future therapeutic interventions in cancer. This review first summarizes the cellular and molecular bases involved in the metabolic pathway and expression of glycolipids, both in normal and tumor cells, paying particular attention to sialosylated glycolipids (gangliosides). The current strategies in the battle against cancer in which glycolipids are key players are then described.

Original languageEnglish (US)
Article number00306
JournalFrontiers in Oncology
Volume3 DEC
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Fingerprint

Glycolipids
Glycosylation
Neoplasms
Therapeutics
Active Immunotherapy
Passive Immunization
Gangliosides
Gene Regulatory Networks
Cytotoxins
Metabolic Networks and Pathways
Clinical Trials
Pathology
Antibodies
Enzymes
Proteins

Keywords

  • Antibodies
  • Cancer
  • Gangliosides
  • Glycolipids
  • Glycosylation
  • Immunotherapy
  • Immunotoxin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Glycosylation of glycolipids in cancer : Basis for development of novel therapeutic approaches. / Daniotti, Jose L.; Vilcaes, Aldo Alejandro; Demichelis, Vanina Torres; Ruggiero, Fernando M.; Rodriguez-Walker, Macarena.

In: Frontiers in Oncology, Vol. 3 DEC, 00306, 01.12.2013.

Research output: Contribution to journalReview article

Daniotti, Jose L. ; Vilcaes, Aldo Alejandro ; Demichelis, Vanina Torres ; Ruggiero, Fernando M. ; Rodriguez-Walker, Macarena. / Glycosylation of glycolipids in cancer : Basis for development of novel therapeutic approaches. In: Frontiers in Oncology. 2013 ; Vol. 3 DEC.
@article{43a3e2a25ce44cabb33d74762eec9ad1,
title = "Glycosylation of glycolipids in cancer: Basis for development of novel therapeutic approaches",
abstract = "Altered networks of gene regulation underlie many pathologies, including cancer. There are several proteins in cancer cells that are turned either on or off, which dramatically alters the metabolism and the overall activity of the cell, with the complex machinery of enzymes involved in the metabolism of glycolipids not being an exception. The aberrant glycosylation of glycolipids on the surface of the majority of cancer cells, associated with increasing evidence about the functional role of these molecules in a number of cellular physiological pathways, has received considerable attention as a convenient immunotherapeutic target for cancer treatment. This has resulted in the development of a substantial number of passive and active immunotherapies, which have shown promising results in clinical trials. More recently, antibodies to glycolipids have also emerged as an attractive tool for the targeted delivery of cytotoxic agents, thereby providing a rationale for future therapeutic interventions in cancer. This review first summarizes the cellular and molecular bases involved in the metabolic pathway and expression of glycolipids, both in normal and tumor cells, paying particular attention to sialosylated glycolipids (gangliosides). The current strategies in the battle against cancer in which glycolipids are key players are then described.",
keywords = "Antibodies, Cancer, Gangliosides, Glycolipids, Glycosylation, Immunotherapy, Immunotoxin",
author = "Daniotti, {Jose L.} and Vilcaes, {Aldo Alejandro} and Demichelis, {Vanina Torres} and Ruggiero, {Fernando M.} and Macarena Rodriguez-Walker",
year = "2013",
month = "12",
day = "1",
doi = "10.3389/fonc.2013.00306",
language = "English (US)",
volume = "3 DEC",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Glycosylation of glycolipids in cancer

T2 - Basis for development of novel therapeutic approaches

AU - Daniotti, Jose L.

AU - Vilcaes, Aldo Alejandro

AU - Demichelis, Vanina Torres

AU - Ruggiero, Fernando M.

AU - Rodriguez-Walker, Macarena

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Altered networks of gene regulation underlie many pathologies, including cancer. There are several proteins in cancer cells that are turned either on or off, which dramatically alters the metabolism and the overall activity of the cell, with the complex machinery of enzymes involved in the metabolism of glycolipids not being an exception. The aberrant glycosylation of glycolipids on the surface of the majority of cancer cells, associated with increasing evidence about the functional role of these molecules in a number of cellular physiological pathways, has received considerable attention as a convenient immunotherapeutic target for cancer treatment. This has resulted in the development of a substantial number of passive and active immunotherapies, which have shown promising results in clinical trials. More recently, antibodies to glycolipids have also emerged as an attractive tool for the targeted delivery of cytotoxic agents, thereby providing a rationale for future therapeutic interventions in cancer. This review first summarizes the cellular and molecular bases involved in the metabolic pathway and expression of glycolipids, both in normal and tumor cells, paying particular attention to sialosylated glycolipids (gangliosides). The current strategies in the battle against cancer in which glycolipids are key players are then described.

AB - Altered networks of gene regulation underlie many pathologies, including cancer. There are several proteins in cancer cells that are turned either on or off, which dramatically alters the metabolism and the overall activity of the cell, with the complex machinery of enzymes involved in the metabolism of glycolipids not being an exception. The aberrant glycosylation of glycolipids on the surface of the majority of cancer cells, associated with increasing evidence about the functional role of these molecules in a number of cellular physiological pathways, has received considerable attention as a convenient immunotherapeutic target for cancer treatment. This has resulted in the development of a substantial number of passive and active immunotherapies, which have shown promising results in clinical trials. More recently, antibodies to glycolipids have also emerged as an attractive tool for the targeted delivery of cytotoxic agents, thereby providing a rationale for future therapeutic interventions in cancer. This review first summarizes the cellular and molecular bases involved in the metabolic pathway and expression of glycolipids, both in normal and tumor cells, paying particular attention to sialosylated glycolipids (gangliosides). The current strategies in the battle against cancer in which glycolipids are key players are then described.

KW - Antibodies

KW - Cancer

KW - Gangliosides

KW - Glycolipids

KW - Glycosylation

KW - Immunotherapy

KW - Immunotoxin

UR - http://www.scopus.com/inward/record.url?scp=84892411944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892411944&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00306

DO - 10.3389/fonc.2013.00306

M3 - Review article

C2 - 24392350

AN - SCOPUS:84892411944

VL - 3 DEC

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 00306

ER -